安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home - mdxhealth
Delivering molecular diagnostic solutions for urologic diseases Mdxhealth is making testing accessible and affordable for all patients © 2025 mdxhealth All Rights Reserved
- Login | MDX Client Portal
Forgot Password? You are using an older browser If you wish to take full advantage of this site please upgrade to a modern browser
- Log in - MDX Portal
Required Fields! Please make sure that the account id and the user name are both filled in
- Shareholder Information - mdxhealth
Mdxhealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers Mdxhealth has been listed on NASDAQ since 2021
- Select mdx for Physicians - mdxhealth
Learn how the Select mdx urine test can reveal your risk A non-invasive urine test (“liquid biopsy”), Select mdx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1) 1 The test provides binary results that, when combined with the patient’s clinical risk factors, help the physician determine whether:
- Confirm mdx for Physicians - mdxhealth
Confirm mdx is the only genomic test that analyzes the broader tissue environment of the prostate to reveal the patient’s true prostate cancer risk that biopsy alone cannot assess Incorporating Confirm mdx into clinical practice improves patient stratification so you can focus on finding aggressive prostate cancer 1 2 3
- Press Releases - mdxhealth
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70 2 million; excluding GPS, revenues up 42%2023 gross margin expanded
|
|
|